CY1119381T1 - Παραγωγα 2-μεθυλομορφολινο πυριδο-, πυραζο- και πυριμιδο-πυριμιδινης ως αναστολεις mtor - Google Patents
Παραγωγα 2-μεθυλομορφολινο πυριδο-, πυραζο- και πυριμιδο-πυριμιδινης ως αναστολεις mtorInfo
- Publication number
- CY1119381T1 CY1119381T1 CY20171100457T CY171100457T CY1119381T1 CY 1119381 T1 CY1119381 T1 CY 1119381T1 CY 20171100457 T CY20171100457 T CY 20171100457T CY 171100457 T CY171100457 T CY 171100457T CY 1119381 T1 CY1119381 T1 CY 1119381T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pyrimidine
- pyrazo
- mtor
- methylmorpholine
- suspensions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
Abstract
Παρέχεται μια ένωση του Τύπου (I), ή ένα φαρμακευτικώς αποδεκτό άλας αυτής. Παρέχονται, επίσης, μέθοδοι για τη παρασκευή μιας ένωσης του Τύπου (1), και η χρήση μιας ένωσης του Τύπου (1) ως φάρμακο και στη θεραπεία του καρκίνου.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82331106P | 2006-08-23 | 2006-08-23 | |
US93877607P | 2007-05-18 | 2007-05-18 | |
PCT/GB2007/003179 WO2008023161A1 (en) | 2006-08-23 | 2007-08-21 | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1119381T1 true CY1119381T1 (el) | 2018-02-14 |
Family
ID=38537521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100457T CY1119381T1 (el) | 2006-08-23 | 2017-04-25 | Παραγωγα 2-μεθυλομορφολινο πυριδο-, πυραζο- και πυριμιδο-πυριμιδινης ως αναστολεις mtor |
Country Status (29)
Country | Link |
---|---|
US (6) | US7902189B2 (el) |
EP (1) | EP2057156B1 (el) |
JP (2) | JP5227321B2 (el) |
KR (1) | KR101438245B1 (el) |
AR (1) | AR062503A1 (el) |
AU (1) | AU2007287430B2 (el) |
BR (1) | BRPI0715888B1 (el) |
CA (1) | CA2659851C (el) |
CL (1) | CL2007002448A1 (el) |
CO (1) | CO6150164A2 (el) |
CY (1) | CY1119381T1 (el) |
DK (1) | DK2057156T3 (el) |
ES (1) | ES2648388T3 (el) |
HR (1) | HRP20170627T1 (el) |
HU (1) | HUE033894T2 (el) |
IL (1) | IL196775A (el) |
LT (1) | LT2057156T (el) |
MX (1) | MX2009001946A (el) |
MY (1) | MY148688A (el) |
NO (1) | NO342383B1 (el) |
NZ (1) | NZ575672A (el) |
PL (1) | PL2057156T3 (el) |
PT (1) | PT2057156T (el) |
RS (1) | RS55881B1 (el) |
RU (1) | RU2445312C2 (el) |
SA (1) | SA07280461B1 (el) |
SI (1) | SI2057156T1 (el) |
TW (1) | TWI406863B (el) |
WO (1) | WO2008023161A1 (el) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2264819C (en) * | 1996-09-04 | 2010-03-23 | Intertrust Technologies Corp. | Trusted infrastructure support systems, methods and techniques for secure electronic commerce, electronic transactions, commerce process control and automation, distributed computing, and rights management |
JP5227321B2 (ja) | 2006-08-23 | 2013-07-03 | クドス ファーマシューティカルズ リミテッド | Mtor阻害剤としての2−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体 |
BRPI0818426A2 (pt) * | 2007-10-15 | 2017-06-13 | Astrazeneca Ab | produto de combinação, uso de um produto de combinação, e, método para tratar câncer |
AU2009215375A1 (en) * | 2008-02-21 | 2009-08-27 | Astrazeneca Ab | Combination therapy 238 |
ES2398423T3 (es) * | 2008-06-20 | 2013-03-19 | Astrazeneca Ab | Composiciones con y procedimiento para pirido[2,3-D]pirimidinas sustituídas con metilmorfolina |
BRPI0911688A2 (pt) * | 2008-07-31 | 2015-07-28 | Genentech Inc | "compostos de pirimidina, composições e métodos de uso" |
EP2308877B1 (en) | 2008-08-05 | 2014-01-22 | Daiichi Sankyo Company, Limited | Imidazopyridin-2-one derivatives |
TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
AR074199A1 (es) | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer. |
CA2751501C (en) * | 2009-02-12 | 2018-01-16 | Merck Serono S.A. | 2-morpholino-pyrido[3,2-d]pyrimidines |
US20120114637A1 (en) * | 2009-05-04 | 2012-05-10 | Santen Pharmaceutical Co., Ltd. | Mtor pathway inhibitors for treating ocular disorders |
EP2445346A4 (en) * | 2009-06-24 | 2012-12-05 | Genentech Inc | OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE |
US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
EP2498780B1 (en) * | 2009-11-12 | 2016-09-07 | F.Hoffmann-La Roche Ag | N-9-substituted purine compounds, compositions and methods of use |
RU2515541C2 (ru) | 2009-11-12 | 2014-05-10 | Ф.Хоффманн-Ля Рош Аг | N-7 замещенные пурины и пиразолопиримидины, их композиции и способы применения |
MX2012005695A (es) | 2009-11-18 | 2012-06-13 | Novartis Ag | Metodos y composiciones para el tratamiento de tumores solidos y otras malignidades. |
WO2011067348A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Mek inhibitor salts and solvates thereof |
WO2011067356A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Polymorphs of a mek inhibitor |
BR112012019459A2 (pt) | 2010-02-03 | 2017-10-17 | Signal Pharm Llc | identificação de mutação de lkb1 como um biomarcador preditivo para sensibilidade para inibidores de tor quinase. |
CN102821759A (zh) | 2010-03-30 | 2012-12-12 | 诺华有限公司 | 用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂 |
JP5918214B2 (ja) | 2010-04-13 | 2016-05-18 | ノバルティス アーゲー | がんを治療するためのサイクリン依存性キナーゼ4またはサイクリン依存性キナーゼ(cdk4/6)阻害剤およびmtor阻害剤を含む組合せ |
MX2012015100A (es) | 2010-06-25 | 2013-05-01 | Novartis Ag | Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina. |
AR084312A1 (es) | 2010-12-16 | 2013-05-08 | Genentech Inc | Compuestos triciclicos inhibidores de la pi3k y composiciones farmaceuticas |
JP2014520811A (ja) | 2011-06-29 | 2014-08-25 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 統合失調症の易罹病性及び認知機能障害と関連付けられるニューロン結合の阻害剤 |
AU2012290056B2 (en) | 2011-08-03 | 2015-03-19 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for LKB1 status |
KR20160027219A (ko) | 2012-05-23 | 2016-03-09 | 에프. 호프만-라 로슈 아게 | 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법 |
BR112015007061B1 (pt) * | 2012-09-28 | 2022-10-04 | Cancer Research Technology Limited | Composto, composição farmacêutica e uso do composto |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
MX361136B (es) | 2013-01-23 | 2018-11-28 | Astrazeneca Ab | Compuestos quimicos. |
WO2014145857A1 (en) * | 2013-03-15 | 2014-09-18 | The Trustees Of Columbia University In The City Of New York | TARGETING THE mTOR PATHWAY IN NEUROLOGICAL DISEASE |
CA2908830C (en) | 2013-04-17 | 2021-12-07 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
CA2908957C (en) | 2013-04-17 | 2021-05-18 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
EP2986321A1 (en) | 2013-04-17 | 2016-02-24 | Signal Pharmaceuticals, LLC | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
AU2014253978B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and a 5-Substituted Quinazolinone Compound for treating cancer |
NZ629230A (en) | 2013-04-17 | 2017-05-26 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
NZ629332A (en) | 2013-04-17 | 2017-05-26 | Signal Pharm Llc | Treatment of cancer with dihydropyrazino-pyrazines |
MX2015014455A (es) | 2013-04-17 | 2016-07-21 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y n-(3-(5-fluoro-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino )fenil)acrilamida para tratar cancer. |
DE102013008118A1 (de) * | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
PE20160874A1 (es) | 2013-05-28 | 2016-09-04 | Astrazeneca Ab | Compuestos quimicos |
JP6401250B2 (ja) | 2013-05-29 | 2018-10-10 | シグナル ファーマシューティカルズ,エルエルシー | 7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((trans)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン、その固体形態の医薬組成物、及びその使用方法 |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
CN106008559B (zh) * | 2015-03-25 | 2020-10-16 | 中国科学院上海药物研究所 | 取代吡啶并嘧啶类化合物的合成工艺 |
WO2017031427A1 (en) * | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
TW201726140A (zh) | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
CN113603675A (zh) * | 2015-12-17 | 2021-11-05 | 默克专利有限公司 | 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途 |
WO2017182495A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity |
WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
WO2018019793A1 (en) | 2016-07-25 | 2018-02-01 | Astrazeneca Ab | N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer |
RU2019138161A (ru) | 2017-05-02 | 2021-06-02 | Революшн Медсинз, Инк. | АНАЛОГИ РАПАМИЦИНА КАК ИНГИБИТОРЫ mTOR |
BR112019027402A2 (pt) | 2017-06-22 | 2020-07-07 | Celgene Corporation | tratamento de carcinoma hepatocelular caracterizado por infecção pelo vírus da hepatite b |
JP7340519B2 (ja) * | 2017-11-06 | 2023-09-07 | メッドシャイン ディスカバリー インコーポレイテッド | mTORC1/2二重阻害剤としてのピリドピリミジン系化合物 |
GB201720989D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
CA3093189A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
CN111971283B (zh) * | 2018-03-26 | 2023-04-14 | 肿瘤研究所基金会 | 具有增强的抗肿瘤作用的新型化合物 |
AU2019262979B2 (en) | 2018-05-01 | 2023-07-06 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
US20190336609A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors |
NL2021185B1 (en) | 2018-06-26 | 2020-01-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Combination Therapy and Use Thereof for Treating Cancer |
CA3118493A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
CN113286594B (zh) * | 2019-01-18 | 2023-12-15 | 南京明德新药研发有限公司 | 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用 |
WO2020224585A1 (zh) | 2019-05-06 | 2020-11-12 | 南京明德新药研发有限公司 | 一种mTORC1/2双激酶活性抑制剂的盐型、晶型及其制备方法 |
WO2021133509A1 (en) * | 2019-12-27 | 2021-07-01 | Angex Pharmaceutical, Inc. | Heterocyclic compounds as mtor inhibitors |
TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
AU2021267161A1 (en) | 2020-05-04 | 2022-12-08 | Amgen Inc. | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use |
BR112023023008A2 (pt) * | 2021-05-04 | 2024-02-15 | Vigil Neuroscience Inc | Compostos heterocíclicos como receptor desencadeador expresso em agonistas de células mieloides 2 e métodos de uso |
WO2023107592A1 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Pyridopyrimidines and methods of their use |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4832899A (el) | 1971-08-28 | 1973-05-02 | ||
US4560685A (en) | 1984-06-18 | 1985-12-24 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics |
DE3445298A1 (de) | 1984-12-12 | 1986-06-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
KR100258391B1 (ko) | 1995-05-10 | 2000-06-01 | 야마우치 히로시 | 아날로그 죠이스틱을 이용한 화상처리시스템 |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
TR199801530T2 (xx) * | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
JP4464466B2 (ja) * | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | 4―アニリノキナゾリン誘導体 |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
ATE359515T1 (de) * | 1997-02-12 | 2007-05-15 | Electrophoretics Ltd | Proteinmarker für lungenkrebs und deren verwendung |
GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
US5990117A (en) | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
GB9900334D0 (en) * | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) * | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
CZ306810B6 (cs) * | 1999-02-10 | 2017-07-19 | Astrazeneca Ab | Použití chinazolinového derivátu jako inhibitoru angiogeneze |
RU2269537C2 (ru) | 1999-09-07 | 2006-02-10 | Зингента Партисипейшнс Аг | Фенилзамещенные гетероциклические 1,3-кетоенолы, способ их получения, гербицидное средство на их основе и способ борьбы с ростом нежелательной растительности |
UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
JP4186355B2 (ja) * | 1999-11-24 | 2008-11-26 | 株式会社デンソー | Csma方式対応無線lan用アンテナ装置及び端末局 |
CA2399358C (en) * | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
CN100345830C (zh) * | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
WO2001092224A1 (en) * | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
CA2508792C (en) | 2002-12-06 | 2013-02-05 | Affinium Pharmaceuticals, Inc. | Heterocyclic compounds, methods of making them and their use in therapy |
MXPA05011523A (es) | 2003-04-30 | 2006-01-23 | Inst For Pharm Discovery Inc | Heteroarilos sustituidos como inhibidores de proteinas de tirosina fosfatasas. |
WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
GB0428475D0 (en) | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
WO2006090169A1 (en) * | 2005-02-25 | 2006-08-31 | Kudos Pharmaceuticals Limited | 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors |
KR20070108916A (ko) * | 2005-02-25 | 2007-11-13 | 쿠도스 파마슈티칼스 리미티드 | Mtor 억제제로서 작용하는 하이드라지노메틸,하이드라조노메틸 및 5-원 복소환 화합물 및 이의항암제로서의 용도 |
EP1899332A1 (en) | 2005-06-24 | 2008-03-19 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c. |
BRPI0611707A2 (pt) | 2005-06-29 | 2012-04-24 | Compumedics Ltd | conjunto de sensor com ponte condutiva |
EA200801045A1 (ru) * | 2005-10-12 | 2008-10-30 | Кэнсер Рисерч Текнолоджи Лтд. | Способы и композиции для лечения иммунных нарушений |
CA2628920C (en) | 2005-11-22 | 2015-12-29 | Kudos Pharmaceuticals Limited | Pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
GB0616747D0 (en) * | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
JP5227321B2 (ja) * | 2006-08-23 | 2013-07-03 | クドス ファーマシューティカルズ リミテッド | Mtor阻害剤としての2−メチルモルホリンピリド−、ピラゾ−及びピリミド−ピリミジン誘導体 |
-
2007
- 2007-08-21 JP JP2009525105A patent/JP5227321B2/ja active Active
- 2007-08-21 KR KR1020097005572A patent/KR101438245B1/ko active IP Right Grant
- 2007-08-21 RS RS20170417A patent/RS55881B1/sr unknown
- 2007-08-21 SI SI200731917A patent/SI2057156T1/sl unknown
- 2007-08-21 MY MYPI20090704A patent/MY148688A/en unknown
- 2007-08-21 PT PT77892776T patent/PT2057156T/pt unknown
- 2007-08-21 LT LTEP07789277.6T patent/LT2057156T/lt unknown
- 2007-08-21 EP EP07789277.6A patent/EP2057156B1/en active Active
- 2007-08-21 AU AU2007287430A patent/AU2007287430B2/en active Active
- 2007-08-21 WO PCT/GB2007/003179 patent/WO2008023161A1/en active Application Filing
- 2007-08-21 US US11/842,930 patent/US7902189B2/en active Active
- 2007-08-21 PL PL07789277T patent/PL2057156T3/pl unknown
- 2007-08-21 CA CA2659851A patent/CA2659851C/en active Active
- 2007-08-21 ES ES07789277.6T patent/ES2648388T3/es active Active
- 2007-08-21 MX MX2009001946A patent/MX2009001946A/es active IP Right Grant
- 2007-08-21 HU HUE07789277A patent/HUE033894T2/en unknown
- 2007-08-21 RU RU2009110261/04A patent/RU2445312C2/ru active
- 2007-08-21 NZ NZ575672A patent/NZ575672A/en not_active IP Right Cessation
- 2007-08-21 BR BRPI0715888-2A patent/BRPI0715888B1/pt active IP Right Grant
- 2007-08-21 DK DK07789277.6T patent/DK2057156T3/en active
- 2007-08-22 SA SA7280461A patent/SA07280461B1/ar unknown
- 2007-08-22 TW TW096131156A patent/TWI406863B/zh active
- 2007-08-22 CL CL200702448A patent/CL2007002448A1/es unknown
- 2007-08-23 AR ARP070103751A patent/AR062503A1/es active IP Right Grant
-
2009
- 2009-01-28 IL IL196775A patent/IL196775A/en active IP Right Grant
- 2009-01-29 NO NO20090443A patent/NO342383B1/no not_active IP Right Cessation
- 2009-02-23 CO CO09017881A patent/CO6150164A2/es unknown
-
2011
- 2011-01-26 US US13/014,275 patent/US8101602B2/en active Active
- 2011-11-30 US US13/307,342 patent/US8435985B2/en active Active
-
2013
- 2013-03-14 JP JP2013051772A patent/JP5629343B2/ja active Active
- 2013-04-09 US US13/859,270 patent/US9102670B2/en active Active
-
2015
- 2015-06-08 US US14/733,257 patent/US9717736B2/en active Active
-
2017
- 2017-04-21 HR HRP20170627TT patent/HRP20170627T1/hr unknown
- 2017-04-25 CY CY20171100457T patent/CY1119381T1/el unknown
- 2017-06-19 US US15/626,282 patent/US10034884B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1119381T1 (el) | Παραγωγα 2-μεθυλομορφολινο πυριδο-, πυραζο- και πυριμιδο-πυριμιδινης ως αναστολεις mtor | |
CY1111721T1 (el) | Ακυλαμινοπυραζολια ως αναστολεις fgfr | |
CY1124117T1 (el) | Ετεροκυκλικες αλκυνυλοβενζολικες ενωσεις και ιατρικες συνθεσεις και χρησεις αυτων | |
SE0402735D0 (sv) | Novel compounds | |
EA201100971A1 (ru) | Производные пиримидининдола для лечения злокачественного новообразования | |
EA201000092A1 (ru) | Тризамещенные пиримидиновые производные для лечения пролиферативных заболеваний | |
EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
ATE450533T1 (de) | Carboxamidderivate | |
CY1113323T1 (el) | Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου | |
DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
SE0401971D0 (sv) | Piperidne derivatives | |
EA201001669A1 (ru) | Замещенные пиримидин-5-карбоксамиды 281 | |
CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
EA201000090A1 (ru) | Тризамещенные производные пиримидина для лечения пролиферативных заболеваний | |
EA201001769A1 (ru) | Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы | |
CY1114140T1 (el) | Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο | |
ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
NO20065904L (no) | Terapeutiske forbindelser | |
TW200738725A (en) | Unsaturated mTOR inhibitors | |
WO2005023759A3 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
EA200801998A1 (ru) | ПИРИДИН[3,4-b]ПИРАЗИНОНЫ | |
NO20065878L (no) | Terapeutiske forbindelser | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
EA200970936A1 (ru) | СОЕДИНЕНИЯ ПИРИДО[2,3-d]ПИРИМИДИН-7-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-АЛЬФА ДЛЯ ЛЕЧЕНИЯ РАКА |